Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Urinary triaosylceramide (Gb3) as a marker of cardiac disease

Urinary triaosylceramide (Gb3) as a marker of cardiac disease

US Patent 9750732 · Granted Sep 5, 2017

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Inhibitors of gangliosides metabolism for the treatment of motor neuron diseases2021
Anaplerotic therapy of huntington disease and other polyglutamine diseases2019
Triheptanoin for the treatment of glucose transport 1 deficiency2018
Triheptanoin for the treatment of glucose transport 1 deficiency2018
Anaplerotic therapy of huntington disease and other polyglutamine diseases2017
Triheptanoin for the treatment of glucose transport 1 deficiency2016
Triheptanoin for the treatment of glucose transport 1 deficiency2016
Establishment of patient- or person-specific cardiac myocyte cell lines from hum2015
Urinary triaosylceramide (GB3) as a marker of cardiac disease2015
Urinary triaosylceramide (GB3) as a marker of cardiac disease2015
Urinary triaosylceramide (GB3) as a marker of cardiac disease2015
Urinary triaosylceramide (GB3) as a marker of cardiac disease2015